SIGN UP

Peter van de Sande, Synaffix CEO

January 5, 2023 10:56 AM EST

Amgen kicks off 2023 dealmaking with busy ADC upstart Synaffix

Paul Schloesser

Associate Editor

Amgen started off the new year with a bang, joining forces with ADC player Synaffix and agreeing to dole out as high as $2 billion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

sponsored

Are programs with compounded GLP-1s safe for your population?